Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage III follicular thyroid cancer
Trial Type:  Treatment
Results 1-9 of 9 for your search:
Start Over
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, NCCNGSK20008, 2012C0074, NCT01723202
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9312, NCI-2013-00554, 2012C0101, RU241210I, OSU 12154, NCT01811212
Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 28313, NCI-2014-00171, 818408, UPCC 28313, NCT02041260
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KO-TIP-001, NCI-2015-01835, NCI-2015-00949, NCT02383927
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over